Hall Capital Management Co. Inc. Has $3.73 Million Holdings in Abbott Laboratories $ABT

Hall Capital Management Co. Inc. lessened its holdings in shares of Abbott Laboratories (NYSE:ABTFree Report) by 0.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,434 shares of the healthcare product maker’s stock after selling 194 shares during the quarter. Abbott Laboratories makes up approximately 1.6% of Hall Capital Management Co. Inc.’s investment portfolio, making the stock its 16th largest position. Hall Capital Management Co. Inc.’s holdings in Abbott Laboratories were worth $3,731,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ABT. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories in the first quarter valued at approximately $27,000. Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the first quarter valued at approximately $28,000. Elequin Capital LP acquired a new position in shares of Abbott Laboratories in the first quarter valued at approximately $30,000. JCIC Asset Management Inc. acquired a new position in shares of Abbott Laboratories in the first quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC acquired a new position in shares of Abbott Laboratories in the first quarter valued at approximately $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Royal Bank Of Canada boosted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Morgan Stanley boosted their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Evercore ISI boosted their price target on Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Leerink Partners started coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $146.24.

View Our Latest Report on Abbott Laboratories

Abbott Laboratories Stock Down 0.5%

NYSE ABT opened at $133.05 on Wednesday. The business has a fifty day moving average price of $132.19 and a two-hundred day moving average price of $131.45. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The stock has a market capitalization of $231.58 billion, a PE ratio of 16.67, a PEG ratio of 2.54 and a beta of 0.69.

Abbott Laboratories (NYSE:ABTGet Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the prior year, the company earned $1.14 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.